Xcout Intel
River BioMedics
River BioMedics is a Dutch biotechnology company headquartered in Enschede, Netherlands, founded in 2018. The company focuses on cardiovascular drug discovery by utilizing proprietary 3D human engineered heart tissue models to address unmet medical needs.
Subscribe to see River BioMedics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
River BioMedics at a glance
River BioMedics is a biotech company headquartered in Netherlands. Its most recent funding round, Seed, raised $2M in January 2022. Xcout tracks 1 named person at River BioMedics, including Marcelo Catarino Ribeiro (Chief Scientific Officer).
River BioMedics leadership
- Marcelo Catarino RibeiroChief Scientific Officer
River BioMedics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $2M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
River BioMedics competitors
A few of River BioMedics's closest competitors — see the full list of competitors and alternatives →
HeartBeat.bio is a biotechnology company founded in 2021 and located at the Vienna BioCenter in Austria, specializing in cardiac drug discovery. The company transforms cardiac drug recovery and development using innovative technologies originating from the Institute of Molecular Biotechnology (IMBA).
Stem Cell Theranostics was, as of November 2014, a privately held biotech company based in Menlo Park, California that was seeking to provide companies developing new small molecule therapeutics with a method to more accurately predict cardiotoxicity and cardiovascular drug efficacy.
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
iOrganBio is a biotechnology company founded in 2024 that develops AI-powered platforms for the precision engineering and manufacturing of human cells and organoids. The company's CellForge platform aims to create reproducible human cell models for research applications, including cardiac disease studies and biological simulation.
Engitix is a biotechnology company that utilizes a proprietary platform based on human Extracellular Matrix (ECM) scaffolds to model and study disease biology. The company develops discovery-stage therapeutics targeting fibrosis, inflammation, and solid tumors, and forms partnerships with pharmaceutical and biotech organizations.
Scenic Biotech is a biotechnology company headquartered in Amsterdam, Netherlands, that advances modifier therapy as an approach to treating genetic disorders by uncovering novel genome pathways.
Get River BioMedics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on River BioMedics in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access